Nippon Venture Capital is the famous VC, which was founded in 1996. The main department of described VC is located in the Tokyo. The fund was located in Asia if to be more exact in Japan.
Considering the real fund results, this VC is 8 percentage points less often commits exit comparing to other organizations. The top amount of exits for fund were in 2010. Deals in the range of 1 - 5 millions dollars are the general things for fund. The high activity for fund was in 2016. Despite it in 2019 the fund had an activity. The fund is generally included in 2-6 deals every year. Opposing the other organizations, this Nippon Venture Capital works on 4 percentage points less the average amount of lead investments.
The fund has exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. We can highlight the next thriving fund investment areas, such as Market Research, Software. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Japan. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Metaps Inc., MaritzCX, WHILL
Besides them, we counted 1 critical employee of this fund in our database.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Nippon Venture Capital, startups are often financed by SMBC Venture Capital, Draper Nexus Ventures, CyberAgent Capital. The meaningful sponsors for the fund in investment in the same round are Nissei Capital, Nissay Capital, Draper Nexus Ventures. In the next rounds fund is usually obtained by SMBC Venture Capital, DBJ Capital, Mitsubishi UFJ Capital.
Related Funds
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Rege Nephro | 07 Oct 2024 | Kyoto, Kyoto Prefecture, Japan | |||
Renalys Pharma | $54M | 17 Jul 2024 | Tokyo, Kantō, Japan | ||
Arsaga Partners | $3M | 27 Jun 2024 | Kawasaki, Kanagawa Prefecture, Japan | ||
YADOKARI | $2M | 07 May 2024 | Yokohama, Kanagawa Prefecture, Japan | ||
ORIGINAL LIFE | $4M | 29 Jan 2024 | Chiyoda, Japan | ||
A10 Lab | $4M | 22 Jan 2024 | Chiyoda, Japan | ||
Cranebio | $2M | 04 Oct 2023 | Tokyo, Kantō, Japan | ||
Awarefy | $2M | 16 Aug 2023 | Akasaka, Kantō, Japan | ||
Issues | $1M | 15 Aug 2023 | Minato, Japan |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Rege Nephro | 07 Oct 2024 | Kyoto, Kyoto Prefecture, Japan | |||
Renalys Pharma | $54M | 17 Jul 2024 | Tokyo, Kantō, Japan | ||
Arsaga Partners | $3M | 27 Jun 2024 | Kawasaki, Kanagawa Prefecture, Japan | ||
YADOKARI | $2M | 07 May 2024 | Yokohama, Kanagawa Prefecture, Japan | ||
ORIGINAL LIFE | $4M | 29 Jan 2024 | Chiyoda, Japan | ||
A10 Lab | $4M | 22 Jan 2024 | Chiyoda, Japan | ||
Cranebio | $2M | 04 Oct 2023 | Tokyo, Kantō, Japan | ||
Awarefy | $2M | 16 Aug 2023 | Akasaka, Kantō, Japan | ||
Issues | $1M | 15 Aug 2023 | Minato, Japan |